This webinar will cover the cardiac and neurologic manifestations of hereditary amyloidosis, diagnostic strategies, and the evolving landscape of therapeutics and their impact on the disease. Specific areas of foci include monitoring for disease progression, effects on quality of life, and recent data on novel transthyretin gene silencers.
Негізгі бет Updates in ATTR Cardiac and Neurological Amyloidosis: What's new and exciting for 2022 and beyond.
Пікірлер: 5